Where is Incyte Corporation (INCY) Headed According to Analysts?

Incyte Corporation (NASDAQ:INCY) is one of the best immunotherapy stocks to buy according to hedge funds. Jefferies reiterated a Buy rating on Incyte Corporation (NASDAQ:INCY) on February 11, setting a price target of $120. The same day, Morgan Stanley also lifted the price target on the stock to $102 from $94 while maintaining an Equal Weight rating on the shares.

Incyte Corporation (NASDAQ:INCY) also received a bullish rating update from Stifel on February 11, with the firm raising the price target on the stock to $120 from $119 while maintaining a Buy rating and noting that it anticipates a “quiet(ish)” first half. However, it still likes the longer-term, ex-Jakafi foundation.

The bullish rating updates came after Incyte Corporation (NASDAQ:INCY) announced financial results for fiscal Q4 and the full year ended December 31, 2025, on February 10, reporting a total revenue of $1.51 billion for the quarter, up 28% compared to the prior year period. Management attributed the growth to an increase in total net product revenue and milestone and contract revenue. Total revenue for the full year reached $5.14 billion, reflecting a growth of 21% compared to the prior year period and primarily driven by growth in the total net product revenue and milestone and contract revenue.

Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics, focusing on oncology, hematology, inflammation, and autoimmunity therapeutic areas.

While we acknowledge the potential of INCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.